Chimeric Antigen Receptor T Cell Therapy in Hematology

被引：9

作者：

Ataca, Pinar ^{[1
]}

Arslan, Onder ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

来源：

TURKISH JOURNAL OF HEMATOLOGY | 2015年 / 32卷 / 04期

关键词：

Chimeric antigen receptor T cell; Hematological malignancies; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; CANCER REGRESSION; GENE-THERAPY; IN-VIVO; LYMPHOCYTES; TRANSDUCTION; LYMPHOMA;

D O I：

10.4274/tjh.2015.0049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell transplantation. Adoptive T cell transfer has been improved to be more specific and potent and to cause less off-target toxicity. Currently, there are two forms of engineered T cells being tested in clinical trials: T cell receptor (TCR) and chimeric antigen receptor (CAR) modified T cells. On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy. Many studies were conducted to evaluate the benefits of this exciting and potent new treatment modality. This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARS, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy.

引用

页码：285 / 294

页数：10

共 65 条

[31] Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [J].

Kochenderfer, James N. ;

Wilson, Wyndham H. ;

Janik, John E. ;

Dudley, Mark E. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Maric, Irina ;

Raffeld, Mark ;

Nathan, Debbie-Ann N. ;

Lanier, Brock J. ;

Morgan, Richard A. ;

Rosenberg, Steven A. .

BLOOD, 2010, 116 (20) :4099-4102

[32]

Kochenderfer JN, J CLIN ONCO IN PRESS

[33] Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene [J].

Lamers, C. H. J. ;

van Elzakker, P. ;

Langeveld, S. C. L. ;

Sleijfer, S. ;

Gratama, J. W. .

CYTOTHERAPY, 2006, 8 (06) :542-553

[34] Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells [J].

Lamers, Cor H. J. ;

van Elzakker, Pascal ;

van Steenbergen, Sabine C. L. ;

Luider, Barbara A. ;

Groot, Corrien ;

van Krimpen, Brigitte A. ;

Vulto, Arnold ;

Sleijfer, Stefan ;

Debets, Reno ;

Gratama, Jan Willem .

CYTOTHERAPY, 2013, 15 (05) :620-626

[35] Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence [J].

Larson, RA ;

Sievers, EL ;

Stadtmauer, EA ;

Löwenberg, B ;

Estey, EH ;

Dombret, H ;

Theobald, M ;

Voliotis, D ;

Bennett, JM ;

Richie, M ;

Leopold, LH ;

Berger, MS ;

Sherman, ML ;

Loken, MR ;

van Dongen, JJM ;

Bernstein, ID ;

Appelbaum, FR .

CANCER, 2005, 104 (07) :1442-1452

[36] Current concepts in the diagnosis and management of cytokine release syndrome [J].

Lee, Daniel W. ;

Gardner, Rebecca ;

Porter, David L. ;

Louis, Chrystal U. ;

Ahmed, Nabil ;

Jensen, Michael ;

Grupp, Stephan A. ;

Mackall, Crystal L. .

BLOOD, 2014, 124 (02) :188-195

[37] PERSPECTIVE Assembly line immunotherapy [J].

Levine, Bruce L. ;

June, Carl H. .

NATURE, 2013, 498 (7455) :S17-S17

[38] Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma [J].

Linette, Gerald P. ;

Stadtmauer, Edward A. ;

Maus, Marcela V. ;

Rapoport, Aaron P. ;

Levine, Bruce L. ;

Emery, Lyndsey ;

Litzky, Leslie ;

Bagg, Adam ;

Carreno, Beatriz M. ;

Cimino, Patrick J. ;

Binder-Scholl, Gwendolyn K. ;

Smethurst, Dominic P. ;

Gerry, Andrew B. ;

Pumphrey, Nick J. ;

Bennett, Alan D. ;

Brewer, Joanna E. ;

Dukes, Joseph ;

Harper, Jane ;

Tayton-Martin, Helen K. ;

Jakobsen, Bent K. ;

Hassan, Namir J. ;

Kalos, Michael ;

June, Carl H. .

BLOOD, 2013, 122 (06) :863-871

[39] Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia [J].

Maude, Shannon L. ;

Frey, Noelle ;

Shaw, Pamela A. ;

Aplenc, Richard ;

Barrett, David M. ;

Bunin, Nancy J. ;

Chew, Anne ;

Gonzalez, Vanessa E. ;

Zheng, Zhaohui ;

Lacey, Simon F. ;

Mahnke, Yolanda D. ;

Melenhorst, Jan J. ;

Rheingold, Susan R. ;

Shen, Angela ;

Teachey, David T. ;

Levine, Bruce L. ;

June, Carl H. ;

Porter, David L. ;

Grupp, Stephan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) :1507-1517

[40] Antibody-modified T cells: CARs take the front seat for hematologic malignancies [J].

Maus, Marcela V. ;

Grupp, Stephan A. ;

Porter, David L. ;

June, Carl H. .

BLOOD, 2014, 123 (17) :2625-2635

← 1 2 3 4 5 6 7 →